{"generic":"Alipogene Tiparvovec","drugs":["Alipogene Tiparvovec"],"mono":{"0":{"id":"930435-s-0","title":"Generic Names","mono":"Alipogene Tiparvovec"},"1":{"id":"930435-s-1","title":"Dosing and Indications","sub":[{"id":"930435-s-1-4","title":"Adult Dosing","mono":"<ul><li>alipogene tiparvovec has centralized marketing authorization by the European Medicines Agency (EMA) for use in the European Union (EU)<\/li><li>confirm diagnosis of familial lipoprotein lipase (LPL) deficiency by genetic testing, and administer only to patients with an LPL protein mass of at least 5% of normal, as determined by ELISA or equivalent methods; measure LPL protein mass in the patient's blood sample against a control sample from healthy volunteers<\/li><li><b>Familial lipoprotein lipase deficiency - Pancreatitis, Severe or multiple attacks despite dietary fat restrictions:<\/b> total dose, 1 x 10(12) genome copies\/kg by multiple IM injections in the legs; dose per IM injection, 1.5 x 10(12) genome copies (0.5 mL); each vial contains 3 x 10(12) genome copies\/mL; for single treatment only, do not readminister; premedicate with cyclosporine 3 mg\/kg\/day ORALLY and mycophenolate mofetil 2 g\/day ORALLY for 3 days before through 12 weeks after administration; premedicate with methylprednisolone 1 mg\/kg IV bolus 30 minutes before IM injections<\/li><\/ul>"},{"id":"930435-s-1-5","title":"Pediatric Dosing","mono":"safety and efficacy not established in pediatric patients less than 18 years old "},{"id":"930435-s-1-6","title":"Dose Adjustments","mono":"<ul><li><b>elderly:<\/b> no dose adjustment required; however, immunosuppressant dose may require adjustment<\/li><li><b>renal impairment:<\/b> no dose adjustment required<\/li><li><b>hepatic impairment:<\/b> no dose adjustment required<\/li><\/ul>"},{"id":"930435-s-1-7","title":"Indications","mono":"<b>Non-FDA Labeled Indications<\/b><br\/>Familial lipoprotein lipase deficiency - Pancreatitis, Severe or multiple attacks despite dietary fat restrictions<br\/>"}]},"3":{"id":"930435-s-3","title":"Contraindications\/Warnings","sub":[{"id":"930435-s-3-9","title":"Contraindications","mono":"<ul><li>bleeding risk, increased (eg, thrombocytopenia); treatment requires multiple IM injections<\/li><li>concomitant use, or use within 1 week before or 1 day after alipogene tiparvovec treatment, of antiplatelet or other anticoagulant medications; correct bleeding parameters before treatment<\/li><li>hypersensitivity to alipogene tiparvovec or any component of the product<\/li><li>immunodeficiency<\/li><li>muscle disease (eg, myositis); treatment requires multiple IM injections<\/li><li>oral contraceptive use; may exacerbate underlying lipoprotein lipase deficiency<\/li><\/ul>"},{"id":"930435-s-3-10","title":"Precautions","mono":"<ul><li>infection, active; postpone treatment until resolved<\/li><li>thromboembolic events may occur; increased risk with spinal anesthesia and multiple IM injections required for treatment; determine risk profile prior to administration, and follow applicable local or international prophylaxis guidelines<\/li><li>donation of blood, organs, tissues, and cells for transplantation by treated patients not recommended<\/li><li>sodium-restricted diet; product contains 47.5 to 105.6 mg sodium per administration<\/li><\/ul>"},{"id":"930435-s-3-11","title":"Pregnancy Category","mono":"Unknown<br\/>"},{"id":"930435-s-3-12","title":"Breast Feeding","mono":"Unknown<br\/>"}]},"4":{"id":"930435-s-4","title":"Drug Interactions","sub":{"1":{"id":"930435-s-4-14","title":"Major","mono":"<ul><li>Abciximab (theoretical)<\/li><li>Acenocoumarol (theoretical)<\/li><li>Anagrelide (theoretical)<\/li><li>Apixaban (theoretical)<\/li><li>Ardeparin (theoretical)<\/li><li>Argatroban (theoretical)<\/li><li>Aspirin (theoretical)<\/li><li>Bivalirudin (theoretical)<\/li><li>Certoparin (theoretical)<\/li><li>Cilostazol (theoretical)<\/li><li>Clopidogrel (theoretical)<\/li><li>Dabigatran Etexilate (theoretical)<\/li><li>Dalteparin (theoretical)<\/li><li>Danaparoid (theoretical)<\/li><li>Desirudin (theoretical)<\/li><li>Dipyridamole (theoretical)<\/li><li>Enoxaparin (theoretical)<\/li><li>Eptifibatide (theoretical)<\/li><li>Fondaparinux (theoretical)<\/li><li>Heparin (theoretical)<\/li><li>Lepirudin (theoretical)<\/li><li>Nadroparin (theoretical)<\/li><li>Parnaparin (theoretical)<\/li><li>Phenindione (theoretical)<\/li><li>Phenprocoumon (theoretical)<\/li><li>Prasugrel (theoretical)<\/li><li>Protein C (theoretical)<\/li><li>Reviparin (theoretical)<\/li><li>Rivaroxaban (theoretical)<\/li><li>Sulfinpyrazone (theoretical)<\/li><li>Ticagrelor (theoretical)<\/li><li>Ticlopidine (theoretical)<\/li><li>Tinzaparin (theoretical)<\/li><li>Tirofiban (theoretical)<\/li><li>Treprostinil (theoretical)<\/li><li>Warfarin (theoretical)<\/li><\/ul>"}}},"5":{"id":"930435-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Contusion (10% or higher)<\/li><li><b>Musculoskeletal:<\/b>Pain in limb (10% or higher)<\/li><li><b>Neurologic:<\/b>Headache (10% or higher)<\/li><li><b>Other:<\/b>Fatigue (10% or higher), Increased body temperature (10% or higher)<\/li><\/ul><b>Serious<\/b><br\/><b>Respiratory:<\/b>Pulmonary embolism (1% to less than 10%)<br\/>"},"6":{"id":"930435-s-6","title":"Drug Name Info","sub":{"2":{"id":"930435-s-6-19","title":"Class","mono":"Endocrine-Metabolic Agent<br\/>"},"3":{"id":"930435-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"}}},"9":{"id":"930435-s-9","title":"Administration","mono":"<ul><li><b>General Information<\/b><br\/>administer by IM injection; do not administer intravascularly<br\/><\/li><li><b>Intramuscular<\/b><br\/><ul><li>vials should be transported and stored frozen (-25 to -15 degrees C) in outer carton to protect from light; use immediately after thawing or store refrigerated at 2 to 8 degrees C, protected from light, for a maximum of 8 hours; do not refreeze; syringes may be stored at not more than 25 degrees C and protected from light for a maximum of 8 hours<\/li><li>allow vials to thaw (about 30 to 45 minutes at room temperature (15 to 25 degrees C)) prior to administration; invert twice gently to ensure even mixing; solution should be clear and colorless without visible particles<\/li><li>administer alipogene tiparvovec by IM injections distributed over muscles of upper and lower legs; use spinal or regional anesthesia (or procedural deep sedation, if contraindicated); use ultrasound or electrophysiological guidance for IM injections<\/li><\/ul><\/li><\/ul>"}}}